Thyroid Eye Disease Market Expands With Targeted Therapies and Improved Diagnosis

Thyroid Eye Disease Market Overview

Thyroid Eye Disease (TED) is an autoimmune inflammatory condition affecting the tissues surrounding the eyes and is strongly associated with thyroid disorders, particularly Graves’ disease. The condition can cause orbital inflammation, eyelid retraction, double vision, periorbital swelling, and proptosis, potentially affecting both appearance and vision. According to DelveInsight, the thyroid eye disease market is being shaped by increasing disease awareness, improved diagnosis, expanding therapeutic options, and the emergence of targeted biologic treatments. The report covers the United States, EU4 countries, the United Kingdom, and Japan, with a study period from 2020 to 2034.

The disease represents the major extrathyroidal manifestation of Graves’ disease and can substantially reduce patients’ quality of life. Its clinical presentation ranges from mild ocular discomfort and dryness to severe manifestations that can threaten vision. Because mild and moderate cases may be overlooked or confused with other orbital or inflammatory conditions, the actual patient population can be difficult to identify. This diagnostic challenge has historically contributed to underdiagnosis and delayed treatment.

Thyroid Eye Disease Epidemiology and Patient Burden

The epidemiological landscape provides important insights into the future development of the thyroid eye disease treatment market. DelveInsight estimates that the total prevalence of TED across the seven major markets was approximately 2.386 million cases in 2022, with the number projected to rise during the forecast period. The United States represented the largest share, with approximately 1.012 million prevalent cases in 2022, accounting for about 42% of the total 7MM population. Germany represented approximately 13%, while Japan accounted for around 8%.

The disease also demonstrates a notable gender distribution, with women representing approximately 80% of diagnosed prevalent cases across the 7MM. The inflammatory phase commonly lasts three to six months but can persist for considerably longer, followed by an inactive fibrotic phase. Reactivation can occur after the disease becomes inactive, further complicating long-term management.

The relationship between TED and autoimmune thyroid disorders also creates an important adjacent opportunity for companies evaluating the hashimotos disease market and broader autoimmune thyroid indications. Although TED is most strongly associated with Graves’ disease, thyroid autoimmunity and abnormal thyroid function remain important considerations during diagnosis and patient management.

Thyroid Eye Disease Diagnosis and Treatment Landscape

Diagnosing TED requires clinical assessment alongside thyroid-related laboratory testing and, when appropriate, orbital imaging. Diagnosis can be relatively straightforward in patients with bilateral proptosis and established hyperthyroidism but becomes more complicated among euthyroid or hypothyroid patients, particularly those presenting with unilateral proptosis. Testing for TSH receptor antibodies, including thyroid-stimulating immunoglobulins and thyrotropin-binding inhibitory immunoglobulins, can support diagnosis. CT and MRI may also help identify orbital abnormalities and exclude alternative causes.